Dr Reddys Custom Pharmaceutical Services (CPS) said it was continuing to invest in its UK facilities in Cambridge and Mirfield, West Yorkshire and plans to grow its services further, the company revealed in an interview with Manufacturing Chemist at CPhI.
Both the Cambridge and Mirfield sites were acquired by Dr Reddys from Dowpharma back in 2008 and now form part of the CPS division, which has its main operational footprint in India, that develops and manufactures APIs for customers across the entire lifecycle of product development – from early clinical to late stage and commercial manufacture.
The company’s growing range of services now includes: high containment capability for HPAPIs, cytotoxics, steroids & prostaglandins as well as chiral products, complex carbohydrate chemistry, PEGylation and formulation expertise such as tailored drug release profiles.
The UK expansion is being carried out in phases, said Manoj Mehrotra, vice president (Head - Global CPS Business). The company moved into its new Chirotech Technology Centre in Cambridge in April 2011 and the UK arm has since gone from 30 to 50 people. It is also developing capability in new areas, such as peptides and continuous processing.
Mirfield is currently being expanded and will continue to produce prostaglandins and chiral intermediates as well as have an increased capacity for activated mPEGs and be able to supply clinical quantities of APIs in the 100 kg range by mid 2012.
Dr Andy Evans, Head of European Business Development, Dr Reddys CPS, said the company can now offer high quality development and manufacturing services covering a broad range of technologies and for all stages of a product’s lifecycle from multiple global locations.
